Tags

Type your tag names separated by a space and hit enter

Mediterranean diet and mild cognitive impairment.
Arch Neurol. 2009 Feb; 66(2):216-25.AN

Abstract

BACKGROUND

Higher adherence to the Mediterranean diet (MeDi) may protect from Alzheimer disease (AD), but its association with mild cognitive impairment (MCI) has not been explored.

OBJECTIVE

To investigate the association between the MeDi and MCI.

DESIGN, SETTING, AND PATIENTS

In a multiethnic community study in New York, we used Cox proportional hazards to investigate the association between adherence to the MeDi (0-9 scale; higher scores indicate higher adherence) and (1) the incidence of MCI and (2) the progression from MCI to AD. All of the models were adjusted for cohort, age, sex, ethnicity, education, APOE genotype, caloric intake, body mass index, and duration between baseline dietary assessment and baseline diagnosis.

MAIN OUTCOME MEASURES

Incidence of MCI and progression from MCI to AD.

RESULTS

There were 1393 cognitively normal participants, 275 of whom developed MCI during a mean (SD) follow-up of 4.5 (2.7) years (range, 0.9-16.4 years). Compared with subjects in the lowest MeDi adherence tertile, subjects in the middle tertile had 17% less risk (hazard ratio [HR] = 0.83; 95% confidence interval [CI], 0.62-1.12; P = .24) of developing MCI and those in the highest tertile had 28% less risk (HR = 0.72; 95% CI, 0.52-1.00; P = .05) of developing MCI (trend HR = 0.85; 95% CI, 0.72-1.00; P for trend = .05). There were 482 subjects with MCI, 106 of whom developed AD during a mean (SD) follow-up of 4.3 (2.7) years (range, 1.0-13.8 years). Compared with subjects in the lowest MeDi adherence tertile, subjects in the middle tertile had 45% less risk (HR = 0.55; 95% CI, 0.34-0.90; P = .01) of developing AD and those in the highest tertile had 48% less risk (HR = 0.52; 95% CI, 0.30-0.91; P = .02) of developing AD (trend HR = 0.71; 95% CI, 0.53-0.95; P for trend = .02).

CONCLUSIONS

Higher adherence to the MeDi is associated with a trend for reduced risk of developing MCI and with reduced risk of MCI conversion to AD.

Links

PMC Free PDF
PMC Free Full Text
Publisher Full Text
Aggregator Full Text

Authors+Show Affiliations

Scarmeas N
Department of Neurology, Columbia University Medical Center, New York, NY 10032, USA. ns257@columbia.edu
Stern Y
No affiliation info available
Mayeux R
No affiliation info available
Manly JJ
No affiliation info available
Schupf N
No affiliation info available
Luchsinger JA
No affiliation info available

MeSH

Age DistributionAge of OnsetAgedAged, 80 and overAlzheimer DiseaseApolipoproteins EBody Mass IndexCognition DisordersCohort StudiesDiet, MediterraneanDisease ProgressionEducational StatusEnergy IntakeEthnic GroupsFemaleHumansIncidenceMaleModels, StatisticalProportional Hazards ModelsSex Distribution

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

19204158

Citation

Scarmeas, Nikolaos, et al. "Mediterranean Diet and Mild Cognitive Impairment." Archives of Neurology, vol. 66, no. 2, 2009, pp. 216-25.
Scarmeas N, Stern Y, Mayeux R, et al. Mediterranean diet and mild cognitive impairment. Arch Neurol. 2009;66(2):216-25.
Scarmeas, N., Stern, Y., Mayeux, R., Manly, J. J., Schupf, N., & Luchsinger, J. A. (2009). Mediterranean diet and mild cognitive impairment. Archives of Neurology, 66(2), 216-25. https://doi.org/10.1001/archneurol.2008.536
Scarmeas N, et al. Mediterranean Diet and Mild Cognitive Impairment. Arch Neurol. 2009;66(2):216-25. PubMed PMID: 19204158.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Mediterranean diet and mild cognitive impairment. AU - Scarmeas,Nikolaos, AU - Stern,Yaakov, AU - Mayeux,Richard, AU - Manly,Jennifer J, AU - Schupf,Nicole, AU - Luchsinger,Jose A, PY - 2009/2/11/entrez PY - 2009/2/11/pubmed PY - 2009/4/10/medline SP - 216 EP - 25 JF - Archives of neurology JO - Arch Neurol VL - 66 IS - 2 N2 - BACKGROUND: Higher adherence to the Mediterranean diet (MeDi) may protect from Alzheimer disease (AD), but its association with mild cognitive impairment (MCI) has not been explored. OBJECTIVE: To investigate the association between the MeDi and MCI. DESIGN, SETTING, AND PATIENTS: In a multiethnic community study in New York, we used Cox proportional hazards to investigate the association between adherence to the MeDi (0-9 scale; higher scores indicate higher adherence) and (1) the incidence of MCI and (2) the progression from MCI to AD. All of the models were adjusted for cohort, age, sex, ethnicity, education, APOE genotype, caloric intake, body mass index, and duration between baseline dietary assessment and baseline diagnosis. MAIN OUTCOME MEASURES: Incidence of MCI and progression from MCI to AD. RESULTS: There were 1393 cognitively normal participants, 275 of whom developed MCI during a mean (SD) follow-up of 4.5 (2.7) years (range, 0.9-16.4 years). Compared with subjects in the lowest MeDi adherence tertile, subjects in the middle tertile had 17% less risk (hazard ratio [HR] = 0.83; 95% confidence interval [CI], 0.62-1.12; P = .24) of developing MCI and those in the highest tertile had 28% less risk (HR = 0.72; 95% CI, 0.52-1.00; P = .05) of developing MCI (trend HR = 0.85; 95% CI, 0.72-1.00; P for trend = .05). There were 482 subjects with MCI, 106 of whom developed AD during a mean (SD) follow-up of 4.3 (2.7) years (range, 1.0-13.8 years). Compared with subjects in the lowest MeDi adherence tertile, subjects in the middle tertile had 45% less risk (HR = 0.55; 95% CI, 0.34-0.90; P = .01) of developing AD and those in the highest tertile had 48% less risk (HR = 0.52; 95% CI, 0.30-0.91; P = .02) of developing AD (trend HR = 0.71; 95% CI, 0.53-0.95; P for trend = .02). CONCLUSIONS: Higher adherence to the MeDi is associated with a trend for reduced risk of developing MCI and with reduced risk of MCI conversion to AD. SN - 1538-3687 UR - https://www.unboundmedicine.com/medline/citation/19204158/Mediterranean_diet_and_mild_cognitive_impairment_ L2 - https://jamanetwork.com/journals/jamaneurology/fullarticle/10.1001/archneurol.2008.536 DB - PRIME DP - Unbound Medicine ER -